Want to see HK:2192 full AI Analyst Report?
2192 Stock Chart & Stats
HK$9.83
-HK$0.01(-0.11%)
At close: 4:00 PM EST
HK$9.83
-HK$0.01(-0.11%)
Day’s Range― - ―
52-Week RangeHK$6.31 - HK$16.84
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.46M
Market Cap
HK$5.59B
Enterprise ValueHK$3.05K
Total Cash (Recent Filing)HK$3.72B
Total Debt (Recent Filing)HK$10.11M
Price to Earnings (P/E)14.5
Beta1.28
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.87%
Share Statistics
EPS (TTM)0.45
Shares Outstanding740,114,140
10 Day Avg. Volume901,132
30 Day Avg. Volume1,461,578
Financial Highlights & Ratios
PEG Ratio2.71
Price to Book (P/B)1.32
Price to Sales (P/S)10.00
P/FCF Ratio52.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.51
Revenue Forecast (FY)HK$758.73M
Bulls Say, Bears Say
Bulls Say
High Profitability MarginsReported very high gross and net margins (~58% and ~52%) indicate the core digital services deliver strong unit economics. Such durable margins for a platform/education business support long-term profitability, fund reinvestment or dividends, and cushion top-line variability.
Exceptionally Conservative Balance SheetAn exceptionally conservative balance sheet with debt-to-equity near zero meaningfully lowers financial risk. That flexibility supports investment, helps absorb downturns without costly refinancing, and preserves strategic optionality over the medium term.
Platform-based Recurring Revenue ModelThe company's revenue mix—digital marketing, medical education and platform services to pharma and physicians—creates repeatable campaigns and subscription-style demand. Platform scale and client stickiness support durable revenue streams and pricing leverage over time.
Bears Say
Material 2025 Revenue DeclineA material top-line decline of -24% in 2025 points to demand or execution sensitivity. Sustained or recurring revenue contractions would pressure operating leverage and challenge the maintenance of high margins, reducing predictability of medium-term earnings.
Weak Cash Conversion And Choppy FCFOperating cash flow covering roughly 0.5–0.6x of net income and choppy free cash flow (sharp 2025 decline) indicates earnings don't reliably convert to cash. This constrains self-funding for growth, dividends or buffers against shocks without using reserves or raising capital.
Moderate Returns On EquityROE near 6–7% is modest, and with near-zero leverage there's limited mechanical upside from financing. That implies shareholder returns rely on organic growth or margin expansion, which have been uneven, making return generation harder absent clear growth re-acceleration.
Medlive Technology Co., Ltd. News
2192 FAQ
What was Medlive Technology Co., Ltd.’s price range in the past 12 months?
Medlive Technology Co., Ltd. lowest stock price was HK$6.31 and its highest was HK$16.84 in the past 12 months.
What is Medlive Technology Co., Ltd.’s market cap?
Medlive Technology Co., Ltd.’s market cap is HK$5.59B.
When is Medlive Technology Co., Ltd.’s upcoming earnings report date?
Medlive Technology Co., Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 41 days.
How were Medlive Technology Co., Ltd.’s earnings last quarter?
Medlive Technology Co., Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.267 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Medlive Technology Co., Ltd. overvalued?
According to Wall Street analysts Medlive Technology Co., Ltd.’s price is currently Overvalued.
Does Medlive Technology Co., Ltd. pay dividends?
Medlive Technology Co., Ltd. pays a Quarterly dividend of HK$0.163 which represents an annual dividend yield of 3.87%. See more information on Medlive Technology Co., Ltd. dividends here
What is Medlive Technology Co., Ltd.’s EPS estimate?
Medlive Technology Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medlive Technology Co., Ltd. have?
Medlive Technology Co., Ltd. has 740,114,140 shares outstanding.
What happened to Medlive Technology Co., Ltd.’s price movement after its last earnings report?
Medlive Technology Co., Ltd. reported an EPS of HK$0.267 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Medlive Technology Co., Ltd.?
Currently, no hedge funds are holding shares in HK:2192
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medlive Technology Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.05%
12-Months-Change
Fundamentals
Return on Equity
3.87%
Trailing 12-Months
Asset Growth
5.66%
Trailing 12-Months
Company Description
Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd., along with its affiliated entities, manages a digital platform tailored for medical professionals, serving both the Chinese mainland and international markets. Through its comprehensive platform, the company delivers a precision marketing and corporate solution encompassing a wide array of services. These include project oversight, clinical supervision, handling of clinical data, biostatistical analysis, drafting of study protocols, medical supervision, patient enrollment, and system support. Furthermore, it offers digital market intelligence, electronic data collection, real-world evidence generation, and the development of application software. Medlive also provides a medical knowledge solution focused on continuing medical education and tools for clinical decision-making, which involves licensing specialized software to physicians and other registered users, including various healthcare practitioners and pharmaceutical corporations. An intelligent patient management solution is another core offering, delivering chronic disease management services that cover online consultations, prescription fulfillment, and patient care facilitated by an Internet hospital. Additionally, it provides condition-specific patient education, involving the creation of content, development of specialized software, and associated support services. Originally established in 1996 as Kingyee Co., Limited, the enterprise adopted the name Medlive Technology Co., Ltd. in 2021. Its corporate headquarters are located in Beijing, China.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Charmacy Pharmaceutical Co., Ltd. Class H
―